PCN99 COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE- CANADIAN PERSPECTIVE
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)71994-5
https://www.valueinhealthjournal.com/article/S1098-3015(11)71994-5/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
151
First Page :
A270
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71994-5&doi=10.1016/S1098-3015(11)71994-5